Jorge Julio Castillo MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-6045
Fax+1 617-582-8608
Dr. Castillo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School and serves as the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 275 peer-reviewed articles and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2005 - 2008
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Autonomous Metropolitan University XochimilcoClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
NH State Medical License 2023 - 2027
MA State Medical License 2013 - 2026
RI State Medical License 2005 - 2014
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Robert A. Kyle Award International Workshop for Waldenstrom Macrolgobulinemia, 2022
- Innovation Dana-Farber Cancer Institute, 2022
Clinical Trials
- Dasatinib In Waldenström Macroglobulinemia Start of enrollment: 2019 Nov 04
Roles: Sponsor-Investigator, Contact, Principal Investigator
- Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab Start of enrollment: 2010 Jul 01
- ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy Start of enrollment: 2021 Nov 16
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.Ramón García-Sanz, Roger G Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen McCarthy
Blood Advances. 2025-12-23 - BCL-2 inhibition in Waldenström macroglobulinaemia and marginal zone lymphoma.Shayna Sarosiek, Uriel Suarez, Maria Fernandez-Turizo, Kristopher A Sarosiek, Jorge J Castillo
British Journal of Haematology. 2025-12-01 - Familial Clusters and Clinical Features, Complications, and Outcomes in 1000 Patients with Waldenström Macroglobulinemia.Andres Ramirez-Gamero, Nickolas Tsakmaklis, Zachary R Hunter, Maria Luisa Guerrera, Alberto Guijosa
Blood Advances. 2025-10-21
Press Mentions
BTK and BCL2 Inhibitors in Waldenström MacroglobulinemiaDecember 12th, 2022
Committees
- Member, IWMF Scientific Advisory Committee 2020 - Present
- Member, NCCN (Myeloma, Waldenstrom and Amyloidosis) 2016 - Present
Professional Memberships
- Member
- Member
- European Haematology AssociationMember
- International Myeloma SocietyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
